Winters K J, Santoro S A, Miletich J P, Eisenberg P R
Cardiovascular Division, Washington University School of Medicine, St. Louis, MO 63110.
Circulation. 1991 Oct;84(4):1552-60. doi: 10.1161/01.cir.84.4.1552.
Platelet activation occurs in vivo during pharmacologic thrombolysis and may contribute to recurrent thrombosis. Plasmin does not directly activate platelets except at high concentrations; thus, the mechanisms for platelet activation during thrombolysis remain undefined. Increases in thrombin activity also occur in patients treated with fibrinolytic agents and may contribute to activation of platelets. We have shown that one mechanism for increased thrombin activity is activation of the coagulation system by plasmin.
In the present study we sought to determine whether activation of platelets in response to pharmacologic activation of plasminogen in plasma is due primarily to plasmin or mediated by increased thrombin activity. Platelet-rich citrated plasma (PRP) was recalcified and incubated with 1,000 IU/ml of streptokinase or 1.0 caseinolytic units/ml of plasmin. Concentrations of fibrinopeptide A, a marker of thrombin activity, increased markedly over 10 minutes in plasma incubated with streptokinase or plasmin, but not in PRP incubated without plasminogen activator. Platelet activation characterized by the secretion of 14C-serotonin occurred within 2-4 minutes after thrombin activity increased. In stirred recalcified PRP, platelet aggregation was accelerated from 3.6 +/- 0.5 to 2.5 +/- 0.3 minutes (p less than 0.01) when incubated with 1,000 IU/ml of streptokinase. Leupeptin and aprotinin, inhibitors of plasmin activity, markedly attenuated platelet activation in response to pharmacologic activation of plasminogen. However, inhibition of thrombin with heparin, hirudin, or D-Phe-D-Pro-L-Arg-chloromethylketone was more effective in inhibiting the acceleration of platelet activation induced by plasminogen activation, despite the elaboration of plasmin activity.
Activation of platelets during coronary thrombolysis may be due in part to increased procoagulant activity induced by plasminogen activation as well as other factors that promote platelet activation in vivo.
在药物溶栓过程中,血小板激活在体内发生,且可能导致复发性血栓形成。除高浓度外,纤溶酶不会直接激活血小板;因此,溶栓过程中血小板激活的机制仍不明确。接受纤维蛋白溶解剂治疗的患者体内凝血酶活性也会增加,这可能促使血小板激活。我们已经表明,凝血酶活性增加的一种机制是纤溶酶激活凝血系统。
在本研究中,我们试图确定血浆中纤溶酶原经药物激活后血小板的激活主要是由纤溶酶引起的,还是由凝血酶活性增加介导的。富血小板枸橼酸盐血浆(PRP)重新钙化后,与1000 IU/ml的链激酶或1.0酪蛋白溶解单位/ml的纤溶酶一起孵育。纤维蛋白肽A是凝血酶活性的标志物,在与链激酶或纤溶酶孵育的血浆中,其浓度在10分钟内显著增加,但在未用纤溶酶原激活剂孵育的PRP中未增加。以14C-5-羟色胺分泌为特征的血小板激活在凝血酶活性增加后2 - 4分钟内发生。在搅拌的重新钙化的PRP中,与1000 IU/ml的链激酶一起孵育时,血小板聚集加速,从3.6±0.5分钟缩短至2.5±0.3分钟(p<0.01)。亮抑酶肽和抑肽酶是纤溶酶活性的抑制剂,可显著减弱因纤溶酶原药物激活而引起的血小板激活。然而,尽管纤溶酶活性有所增强,但用肝素、水蛭素或D-苯丙氨酸-D-脯氨酸-L-精氨酸-氯甲基酮抑制凝血酶在抑制纤溶酶原激活诱导的血小板激活加速方面更有效。
冠状动脉溶栓过程中血小板的激活可能部分归因于纤溶酶原激活诱导的促凝血活性增加以及体内其他促进血小板激活的因素。